<DOC>
	<DOCNO>NCT02045589</DOCNO>
	<brief_summary>The purpose study determine safety tolerability three intratumoral injection VCN-01 combine Abraxane®/gemcitabine , determine recommend phase II dose VCN-01 combined Abraxane®/gemcitabine .</brief_summary>
	<brief_title>A Phase I Dose Escalation Study Intratumoral VCN-01 Injections With Gemcitabine Abraxane® Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description>Investigational treatment dose-escalation regimen consist three VCN-01 intratumoral injection ( every 28 day dose ) combination intravenous Abraxane® gemcitabine .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Male/Female patient age 18 year Patients must provide write informed consent Life expectancy 3 month Patients willing comply treatment followup , accept biopsy day 29 initiation treatment Patients histologically confirm diagnosis unresectable pancreatic adenocarcinoma symptom related primary tumor . Abraxane® plus Gemcitabine appropriate standard care administer . ECOG Performance status 0 1 Adequate baseline organ function ( hematologic , liver , renal nutritional ) Use reliable method contraception fertile men woman Active infection serious illness autoimmune disease Treatment live attenuate vaccine last three week Known chronic liver disease ( liver cirrhosis , chronic hepatitis ) Treatment another investigational agent within five halflives prior VCN01 infusion Viral syndrome diagnose two week inclusion Chronic immunosuppressive therapy Known concurrent malignant hematologic solid disease Pregnancy lactation . Patients must agree use effective contraception surgically sterile . Patients receive fulldose anticoagulant / antiplatelet therapy Patients Li Fraumeni syndrome previous know retinoblastoma protein pathway germinal deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Pancreatic adenocarcinoma</keyword>
	<keyword>Locally advanced</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Oncolytic virus</keyword>
	<keyword>Abraxane®</keyword>
</DOC>